GH
Therapeutic Areas
BioPorto Diagnostics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ProNephro AKI (NGAL) | Risk assessment of moderate to severe Acute Kidney Injury (pediatrics, 3 months-22 years) | Commercial |
| The NGAL Test™ | Risk assessment and diagnosis of Acute Kidney Injury (broad population) | Commercial |
| NGAL ELISA Kits | Preclinical & Clinical Research (RUO) | Commercial |
| Regulatory Expansion (Adult Indication) | Risk assessment of AKI in adult populations | Regulatory Development |
Leadership Team at BioPorto Diagnostics
CB
Carsten Buhl
Group CEO
NH
Niels Høy Nielsen
EVP & CFO
JZ
Jennifer Zonderman
SVP Global Marketing & Commercialization
UK
Ursula Klause
SVP Global Clinical & Technical Development
JD
Jens Due Olsen
Chairman of the Board
HJ
Henrik Juuel
Vice Chairman of the Board
MT
Mats Thorén
Board Member
DH
Donna Haire
Board Member